Boehringer Ingelheim USA Corporation

FDA approved zolbetuximab-clzb (Vylov) plus chemotherapy for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, addressing unmet need in PD-L1–low/HER2-negative patients. Routine CLDN18.2 testing is crucial for targeted therapy in previously non-targetable populations.

Boehringer Ingelheim launches VETMEDIN® Solution, the first FDA-approved oral solution for managing CHF in dogs due to MMVD or DCM. This new liquid option complements the existing VETMEDIN® Chewable Tablets, offering a convenient treatment for dogs with heart failure.

FDA approves pimobendan oral solution (Vetmedin Solution) for treating CHF in dogs with MMVD or DCM, marking the first oral solution for this use. Vetmedin brand has been on the market for 25 years, with studies showing pimobendan increases survival and quality of life in dogs with heart disease. Adverse effects include poor appetite, lethargy, and diarrhea, with sudden death reported in 6% of cases.

Walgreens plans to close 1,200 stores over three years due to $3 billion loss, focusing on its retail pharmacy-led legacy. Despite operating losses of $14 billion, its clinical trials business remains unaffected, aiming to address lack of representation and accessibility. Walgreens has partnerships with Boehringer Ingelheim and Biomedical Advanced Research and Development Authority, and has recruited over five million patients.

Walgreens plans to close 1,200 stores over 3 years, focusing on its retail pharmacy-led legacy. Despite operating losses, its clinical trials business remains unaffected, with ongoing partnerships and recruitment efforts targeting diverse populations.

The Antihistamine Drugs Market is projected to grow from USD 279.74 million in 2024 to USD 381.39 million by 2030, driven by rising allergies, a growing geriatric population, and innovations in drug formulation. Key players include Johnson & Johnson, Sanofi, Pfizer, and Bayer. Challenges include market saturation, side effects, and stringent regulations.

The global biosimilars market is projected to reach $150.3 billion by 2033 (CAGR of 17.7%), driven by their cost-effectiveness and expanding patient access. The FDA has approved 60 biosimilar products, with recent regulatory shifts easing interchangeability requirements. The EMA promotes a unified stance on biosimilars, allowing their interchangeability. Technological advancements and strategic adaptations by biopharmaceutical companies aim to streamline biosimilar development and market entry. Biosimilars have saved $23.6 billion in the U.S. healthcare system since 2015, enhancing patient access to treatments.

The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.

FDA approves Bimzelx, the first interleukin-17F and -17A inhibitor, for moderate to severe hidradenitis suppurativa in adults, based on BE HEARD trials results.